In mouse models of AML, treatment with SIRT5 inhibitors or genetic ablation of SIRT5 significantly delays leukemia progression and extends survival, confirming that SIRT5 (and, by extension, protein malonylation) is a drug target (Yan et al. 2021). Here, SIRT5 is linked to acute myeloid leukemia.